Regenxbio Ownership
| RGNX Stock | USD 10.01 0.46 4.82% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 50.6 M | Current Value 50.8 M | Avarage Shares Outstanding 34.8 M | Quarterly Volatility 10.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Regenxbio |
Regenxbio Stock Ownership Analysis
About 92.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.65. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Regenxbio has Price/Earnings To Growth (PEG) ratio of 0.26. The entity recorded a loss per share of 5.01. The firm had not issued any dividends in recent years. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland. Regenxbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 372 people. To find out more about Regenxbio contact Kenneth Mills at 240 552 8181 or learn more at https://www.regenxbio.com.Regenxbio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regenxbio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regenxbio backward and forwards among themselves. Regenxbio's institutional investor refers to the entity that pools money to purchase Regenxbio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aquilo Capital Management, Llc | 2024-09-30 | 930.7 K | Goldman Sachs Group Inc | 2024-06-30 | 649.2 K | Adar1 Capital Management Llc | 2024-09-30 | 569 K | Assenagon Asset Management Sa | 2024-09-30 | 559.9 K | Northern Trust Corp | 2024-09-30 | 488 K | Charles Schwab Investment Management Inc | 2024-09-30 | 417.7 K | Sonic Gp Llc | 2024-09-30 | 403.1 K | Rtw Investments, Llc | 2024-06-30 | 350 K | Bank Of New York Mellon Corp | 2024-06-30 | 339.5 K | Blackrock Inc | 2024-06-30 | 8.6 M | Redmile Group, Llc | 2024-09-30 | 4.9 M |
Regenxbio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regenxbio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regenxbio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regenxbio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Regenxbio's latest congressional trading
Congressional trading in companies like Regenxbio, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Regenxbio by those in governmental positions are based on the same information available to the general public.
| 2019-11-14 | Representative Peter Welch | Acquired Under $15K | Verify |
Regenxbio Outstanding Bonds
Regenxbio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regenxbio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regenxbio bonds can be classified according to their maturity, which is the date when Regenxbio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Regenxbio Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.